Untargeted Metabolomics for Primary Aldosteronism (PUMPAP)

Pilot Untargeted Metabolomics for Primary Aldosteronism in Plasma (PUMPAP)

Primary aldosteronism (PA) is a common and likely under-diagnosed cause of secondary hypertension with associated cardiovascular morbidity and mortality. Current diagnosis comprises screening, confirmatory testing and sub-type classification (lateralisation) to distinguish unilateral disease (requiring surgery) from bilateral disease (requiring medical management). This multi-step process is complex and variable with a lack of uniformity in diagnostic protocols, standardised/reference assay methodologies, and diagnostic thresholds. There is evidence in the literature that targeted serum steroid panels may have a role in diagnosis of PA, and both targeted steroid panels and untargeted metabolomics in serum and urine are a promising area of research.

This study aims to identify and recruit participants (n=40; 20 with confirmed PA and 20 with other causes of hypertension) willing to donate lithium heparin plasma for a metabolomics pilot study. This plasma will be interrogated through untargeted metabolomics using gas/liquid chromatography-mass-spectrometric methods and computational data processing to allow power calculations and inform experimental design for future studies. The utility of metabolites from the metabolomics dataset will be evaluated by comparison against current biomarkers for screening, diagnosis and lateralisation as well as radiology and histology acquired through routine diagnostic work-up. The long-term aim for larger studies is to identify suitable candidate analytes in plasma for future development into targeted, clinically-useful analyte panels.

Study Overview

• Status: Recruiting
• Conditions: Primary Aldosteronism
• Intervention / Treatment: Diagnostic test: Untargeted metabolomics

Detailed Description

Participant Recruitment

• Suitable participants will be identified by members of their care teams, for whom screening, confirmatory testing and lateralisation will be / have been completed at LUHFT.
• Potential participants will be approached by a member of the study team seeking consent. Saline infusion testing and adrenal vein sampling are key points in the diagnostic work-up for participant recruitment for non-PA and PA cohorts, respectively.
• Consenting participants will have lithium heparin plasma collected and stored until the requisite sample size has been reached (n=40; 20 with PA and 20 with PA excluded by aldosterone:renin ratio at screening or saline infusion confirmatory testing). A lithium heparin tube will be used for routine renal profiles requested as part of saline infusion tests or adrenal vein sampling to avoid requirements for any additional blood tubes. The sample will be centrifuged and separated into two aliquots. One aliquot for metabolomic analysis at the University of Liverpool and one for storage within LUHFT until the end of the study (2 years) in case data validation is required. Clinical, biochemical, radiological and histological information from routine care will help to classify participants into PA (n=20) and non-PA (n=20) groups, as well as to assign lateralisation status. Ideally there will be equal representation from unilateral left, unilateral right and bilateral disease in the PA sub-set.
• Recruitment will close after 18 months.

Laboratory Analysis

• Untargeted metabolomics analysis using chromatography-mass spectrometric methods will be performed on lithium heparin plasma from all consenting participants. An aliquot of this sample will be transferred to the University of Liverpool for analysis and used to destruction (with no backwards transfer).

Data Analysis

• Computation analysis of the data set will be used to screen for novel PA biomarkers that could be further investigated in later studies.
• Univariate and multivariate methods will be applied. These will include univariate statistical and AUROC calculations, adjusted logistic regression techniques, unsupervised (clustering/visualisation) and supervised (classifier-based) multivariate methods
• Power calculations and pilot data set analysis will inform future experimental design.

Sample Storage

• Primary aliquots will be stored at LUHFT for up to 18 months awaiting analysis. They will then be transferred in one batch to the University of Liverpool and used to destruction.
• Secondary aliquots of biological material (which are intended as a back-up in case data validation is required) will be stored under appropriate conditions to preserve integrity until the end of the study. Samples will be disposed of after completion of the pilot study (2 years) in line with routine laboratory practice.

Data storage

• Storage of analytical and metadata will be for a period of five years. It will be stored on a secure computer on the Royal Liverpool University Hospital (RLUH) network.

• Study Type: Observational
• Enrollment (Estimated): 40

Contacts and Locations

• Study Contact: Name: Sarah Davies, MChem MSc; Phone Number: 0151 706 4245; Email: sarah.davies@liverpoolft.nhs.uk
• Study Contact Backup: Name: Andrew Davison, BSc MSc PhD; Phone Number: 0151 706 4011; Email: andrew.davison@liverpoolft.nhs.uk

Study Locations

• United Kingdom
  • Merseyside
    • Liverpool, Merseyside, United Kingdom, L9 7AL
      • Recruiting
      • Liverpool University Hospitals NHS Foundation Trust
      • Contact: Andrew Davison; Phone Number: 0151 525 5980; Email: Andrew Davison <Andrew.Davison@liverpoolft.nhs.uk>

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Eligible participants will be undergoing diagnostic work-up for PA, meet the above eligibility criteria, and give informed consent to participate.

Description

Inclusion Criteria:

Screening for PA to be performed in people with:

• sustained blood pressure (BP) above 150/100 mm Hg on each of three measurements obtained on different days, with hypertension (BP >140/90 mm Hg) resistant to three conventional antihypertensive drugs (including a diuretic), or controlled BP (<140/90 mm Hg) on four or more antihypertensive drugs.
• hypertension and spontaneous or diuretic-induced hypokalaemia.
• hypertension and adrenal incidentaloma.
• hypertension and sleep apnoea.
• hypertension and a family history of early onset hypertension or cerebrovascular accident at a young age (<40 years).
• all hypertensive first-degree relatives of people with PA.

Subset of people being screened for PA who are eligible for inclusion in this study:

• 18 years of age or older.
• People under the care of LUHFT.
• Able to give informed consent.
• Having lithium heparin plasma samples collected as part of their routine care.

Exclusion Criteria:

• Under 18 years of age.
• Unable to give informed consent.
• Insufficient clinical/biochemical/radiological/histological information to accurately assign patients to PA or non-PA subsets.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Confirmed Primary Aldosteronism	Diagnostic test: Untargeted metabolomics; Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
Non-Primary Aldosteronism; Other causes of hypertension	Diagnostic test: Untargeted metabolomics; Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Untargeted metabolomics	Identification of candidate biomarkers	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Future experimental design	Experimental design for future studies, providing this is supported by the pilot data.	Can commence when data is available (18-24 months).
Publication	Publication of any analytical findings related to this study.	Can start when data is available (18-24 months). Publication likely to be after study completion at 2 years.
Power calculations	Power calculations (required for future experimental design). Based on doi: 10.1021/acs.analchem.6b00188 and doi: 10.1038/s41596-021-00579-1.	Can commence when data is available (18-24 months).

Collaborators and Investigators

• Sponsor: Liverpool University Hospitals NHS Foundation Trust
• Investigators: Principal Investigator: Sarah Davies, MChem MSc, Liverpool University Hospitals NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2023
• Primary Completion (Estimated): January 19, 2025
• Study Completion (Estimated): January 19, 2025

Study Registration Dates

• First Submitted: December 30, 2022
• First Submitted That Met QC Criteria: October 6, 2023
• First Posted (Actual): October 10, 2023

Study Record Updates

• Last Update Posted (Actual): February 15, 2024
• Last Update Submitted That Met QC Criteria: February 14, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Plasma; Pilot; Primary Aldosteronism; Untargeted Metabolomics
• Additional Relevant MeSH Terms: Endocrine System Diseases; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Hyperaldosteronism
• Other Study ID Numbers: LHS001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Patient identifiable data will not be shared outside the study team. Data will be pseudo-anonymised (mapped onto a unique study ID) by the study team to remove direct traceability to the participant and allow data to be shared between participating sites.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No